Abstract:The effectiveness of commonly adopted therapeutic regimen is low for treating triple-negative breast cancer (TNBC), especially for inoperable patients at advanced stage. Herein, we reported a nano-based recipe for orthotopic and metastatic TNBC management by potentiating the deep penetration of antitumor agents in solid tumors and remodeling the tumor immune microenvironment through combinational chemoimmunotherapy. Specifically, doxorubicin (DOX) was loaded in DSPE-PEG2000-modified poly(amidoamine) (PAMAM) dendrimer to obtain small-sized DOX@P nanoparticles, which were further inserted into the phospholipid monolayer of imiquimod (R837)-encapsulated reconstituted high-density lipoprotein (rHDL) to acquire R@rHDP. Finally, M2 macrophage-targeting peptide (M2pep) was modified on the surface of R@rHDP to obtain R@rHDP-M2pep nanoparticles with special targeting ability towards M2-like tumor-associated macrophages (TAMs). Upon intravenous injection, R@rHDP-M2pep actively anchored TNBC sites owing to the natural tumor targeting potential of rHDL. Once reaching tumor sites, small-sized DOX@P was released from large-sized R@rHDP-M2pep due to the breakdown of imine bond in acidic tumor microenvironment (TME), further carrying DOX into the deep tumor core to exert chemotherapeutic effect. On the other hand, the remaining R@rH-M2pep continued to target M2-like TAMs to deliver R837 for effective polarization of TAM phenotype from protumoral M2-like into antitumoral M1-like type. Consequently, the immunosuppressive TME was remodeled to facilitate improved immunotherapeutic performance. Hence, the designed R@rHDP-M2pep nanoparticles displayed potent antitumor efficacy against TNBC, which not only remarkably suppressed orthotopic tumor growth, but also prevented the lethal lung metastasis of TNBC, largely prolonging the survival time of mice suffered from TNBC. Altogether, the proposed strategy exhibited promising research value in advancing the therapeutic protocols for TNBC.

Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy

Polydopamine-Functionalized CA-(PCL-ran-PLA) Nanoparticles for Target Delivery of Docetaxel and Chemo-photothermal Therapy of Breast Cancer.

Enhanced Bioreduction-Responsive Diselenide-Based Dimeric Prodrug Nanoparticles for Triple Negative Breast Cancer Therapy.

Dimeric camptothecin-loaded RGD-modified targeted cationic polypeptide-based micelles with high drug loading capacity and redox-responsive drug release capability.

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Enhanced Tumor Penetration and Chemotherapy Efficiency by Covalent Self-Assembled Nanomicelle Responsive to Tumor Microenvironment

Tumor-Targeting Micelles Based on Linear Dendritic PEG-PTX8 Conjugate for Triple Negative Breast Cancer Therapy

Co‐delivery CPT and PTX prodrug with a photo/thermo‐responsive nanoplatform for triple‐negative breast cancer therapy

Self‐Promoted Targeting Delivery of Nanodrug Through Chemotherapeutic Upregulation of CD47 for Triple Negative Breast Cancer Therapy

LHRH‐Targeted Redox‐Responsive Crosslinked Micelles Impart Selective Drug Delivery and Effective Chemotherapy in Triple‐Negative Breast Cancer

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer

Nanomicelle-Based Redox-Responsive Dual-Prodrug for Synergistic Breast Cancer Chemo-Immunotherapy

Co-assembly of polymeric conjugates sensitizes neoadjuvant chemotherapy of Triple-Negative Breast Cancer with reduced systemic toxicity

Smart and Hyper-Fast Responsive Polyprodrug Nanoplatform for Targeted Cancer Therapy.

Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.

Mitochondria-Specific Anticancer Drug Delivery Based on Reduction-Activated Polyprodrug for Enhancing the Therapeutic Effect of Breast Cancer Chemotherapy.

Size-switchable and Dual-Targeting Nanomedicine for Cancer Chemoimmunotherapy by Potentiating Deep Tumor Penetration and Antitumor Immunity

Camptothecin Nanoprodrug Possessing Dual Responsiveness to Endolysosomal Ph and Cytosolic Redox for Amplified Cytotoxic Potency.

Endosomal pH, Redox Dual-Sensitive Prodrug Micelles Based on Hyaluronic Acid for Intracellular Camptothecin Delivery and Active Tumor Targeting in Cancer Therapy

Porphyrin Centered Paclitaxel Tetrameric Prodrug Nanoassemblies as Tumor‐Selective Theranostics for Synergized Breast Cancer Therapy

Redox-responsive Amphiphilic Camptothecin Prodrug Nanoparticles for Targeted Liver Tumor Therapy.